Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.
In most developing countries, paediatric tuberculosis is treated with split tablets leading to potential inaccuracy in the dose delivery and drug exposure. There is no data on the quality of first-line drugs content in split fixed-dose combination tablets.To determine Isoniazid, Pyrazinamide and Rif...
Main Authors: | Thomas Pouplin, Pham Nguyen Phuong, Pham Van Toi, Julie Nguyen Pouplin, Jeremy Farrar |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4086978?pdf=render |
Similar Items
-
The solubility enhancement and the stability assessment of rifampicin, isoniazid and pyrazinamide in aqueous media
by: Chen, Yu-Jen
Published: (2000) -
Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients
by: McIlleron, Helen
Published: (2014) -
The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
by: Lin HS, et al.
Published: (2016-03-01) -
Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: Is anti-HCV a risk factor?
by: Lysandro Alsina Nader, et al.
Published: (2010-01-01) -
Dextran fractional clearance studies in acute dengue infection.
by: Julie Nguyen-Pouplin, et al.
Published: (2011-08-01)